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Abstract: The introduction of new immunosuppressive agents into clinical transplantation in the 
1990s has resulted in excellent short-term graft survival. Nonetheless, extended long-term graft 
outcomes have not been achieved due in part to the nephrotoxic effects of calcineurin inhibitors 
(CNIs) and the adverse effects of steroid on cardiovascular disease risk factors. Induction therapy 
with lymphocyte depleting antibodies has originally been introduced into renal transplantation 
to provide intense immunosuppression in the early post-transplant period to prevent allograft 
rejection. Over the past half decade, induction therapy with both non-lymphocyte depleting 
(basiliximab and daclizumab) and lymphocyte-depleting antibodies (antithymocyte antibodies, 
OKT3, alemtuzumab) has increasingly been utilized in steroid or CNI sparing protocols in the 
early postoperative period. Alemtuzumab is a humanized monoclonal antibody targeted against 
CD52 on the surface of circulatory mononuclear cells. The ability of alemtuzumab (Campath-1H) 
to provide rapid and profound depletion of lymphocytes from the peripheral blood has sparked 
interest in the use of this agent as induction therapy in steroid and/or CNI minimization or 
avoidance protocols. This article provides an overview of the literarure on the evolving role of 
alemtuzumab in renal transplantation.
Keywords: alemtuzumab, Campath-1H, induction, renal transplantation, calcineurin inhibitor 
minimization, steroid avoidance
Introduction
Aggressive T-cell depletion in the peritransplant period has been suggested to 
prevent immune engagement during a period where there is a maximal drive towards 
lymphocyte activation, proliferation, and ultimately rejection.1 Experimental studies 
have shown that perioperative lymphocyte depletion using pan-T-cell immunotoxins 
or other depleting antibodies induces tolerance in some rodents, canine, and nonhuman 
primate models.2–3 Although immune tolerance has not been successfully achieved in 
clinical transplantation, lymphocyte depleting agents such as antithymocyte antibodies, 
or more recently alemtuzumab has increasingly been used as induction therapy in solid 
organ transplantation to induce a state of near-tolerance or “prope tolerance” whereby 
allografts can be maintained with reduced immunosuppression.
Alemtuzumab (Campath-1H) is a humanized immunoglobulin IgG1 monoclonal 
antibody directed against CD52, a cell surface glycoprotein expressed on circulating 
T-and B-cells and to a lesser extent on natural killer cells, monocytes, and macrophages. 
It has been suggested that after binding to its target, alemtuzumab causes cell death 
through complement-mediated cell lysis and antibody-mediated cellular cytotoxicity.4–5 
In vitro studies suggested that alemtuzumab may also enhance lymphocyte apoptosis 
through both caspase-dependent and caspase-independent pathways.6 Alemtuzumab 
was approved by the US Food and Drug administration for the treatment of lymphoid 
malignancies in 1999. It has been used off-label in bone marrow transplantation to 
prevent graft versus host disease and to treat various autoimmune diseases such as Drug Design, Development and Therapy 2009:3 42
Pham et al
rheumatoid arthritis, scleroderma, and multiple sclerosis. 
Because of its rapid and profound lymphocyte depleting 
effects, alemtuzumab has increasingly been used off-label 
as induction therapy in renal transplantation as a means to 
allow safe avoidance or minimization of steroid or CNI 
therapy. Clinical studies evaluating the safety and efﬁ  cacy of 
antibody pre-conditioning with alemtuzumab in conjunction 
with reduction in maintenance immunosuppression have 
yielded variable and conflicting results. In the current 
article we provide an overview of the literature and present 
our opinion on the evolving role of alemtuzumab in renal 
transplantation.
Early experiences
Alemtuzumab induction therapy in steroid 
avoidance and calcineurin inhibitor 
minimization protocols
Alemtuzumab was ﬁ  rst introduced in renal transplantation 
in 1998 by Calne and colleagues.7 In a small nonrandomized 
pilot study consisting of 13 primary deceased donor renal 
transplants, the authors demonstrated that the use of 
alemtuzumab as induction therapy (total 2 doses of 20 mg) 
followed by half-dose cyclosporine monotherapy resulted in 
satisfactory short-term outcomes. Patient and graft survival 
were 100% at 6-to 11-month follow-up. One patient devel-
oped steroid responsive biopsy-proven acute rejection. 
A second patient with impaired graft function showed no 
evidence of acute rejection on biopsy. No serious adverse 
events occurred during the study period.
The same group of investigators reported the long-term 
efﬁ  cacy and safety of alemtuzumab induction therapy in 
deceased donor renal transplantation. In the extension 
of a single-center study consisting of 33 renal allograft 
recipients, Watson and colleagues8 demonstrated that the 
use of alemtuzumab as induction therapy (20 mg given 
intravenously on day 0 and day 1 after transplant) followed by 
half-dose cyclosporine monotherapy resulted in satisfactory 
5-year patient and graft survival comparable to that seen 
with standard triple immunosuppression consisting of 
cyclosporine (CSA), azathioprine, and prednisolone while 
avoiding steroid therapy. Although the incidence of acute 
rejection was similar between the two treatment groups at 5 
years (alemtuzumab vs conventional triple therapy: 31.5% 
vs 33.6%, respectively), the pattern of rejection was different 
with 14% patients in the alemtuzumab group experiencing 
rejection over 1year post- transplant compared to none in the 
control group. Graft and patient survival and serum creatinine 
at 5-year follow up were similar in both groups despite the 
use of lower CSA concentration in the alemtuzumab group. 
The incidence of infections, de novo malignancies and 
serious adverse events were also comparable between the 
two treatment groups.
Alemtuzumab induction therapy without 
maintenance immunosuppression
Kirk and colleagues9 hypothesized that aggressive 
pretransplant treatment with alemtuzumab would deplete 
peripheral and secondary lymphoid T cells and establish 
favorable conditions for the development of tolerance. In a 
pilot study consisting of 7 non-sensitized recipients of living 
donor kidneys, 3 to 4 doses of alemtuzumab (at 0.3 mg/kg per 
dose) were administered intravenously in the peri-transplant 
period without additional maintenance immunosuppression. 
Despite profound lymphocyte depletion in the periphery and 
secondary lymphoid tissues, all patients developed acute 
rejection within the ﬁ  rst month that were characterized 
predominantly by monocytic (not lymphocytic) inﬁ  ltrates 
with only rare T cells in the periphery blood or allograft. 
Most episodes were reversed with steroid (n = 5). One 
patient required OKT3 and one responded to sirolimus alone. 
Sirolimus maintenance therapy was initiated in all patients. 
There were no episodes of late acute rejection at 12 month 
follow-up. This study demonstrated that alemtuzumab 
alone does not induce tolerance in clinical transplantation. 
A prominent role for early responding monocytes in human 
allograft rejection has been suggested.
Alemtuzumab induction and short-term 
deoxypergualin monotherapy
The failure of alemtuzumab induction alone to induce 
tolerance in humans and the observation that lymphopenic 
rejections were characterized predominantly by graft 
inﬁ  ltration with monocytes and macrophages have led 
Kirk and colleagues10 to hypothesize that monocytes 
were under-immunosuppressed by T-cell depletion alone 
and hence available as alternative effector cells for 
T-cell depletion-resistant rejection. The same group of 
investigators conducted a trial to determine whether T-cell 
depletion with alemtuzumab in combination with a brief 
course of deoxyspergualin (DSG), a drug with inhibitory 
effect on monocytes and macrophages would induce 
tolerance in recipients of renal allograft transplants. Five 
recipients of primary live donor kidneys were treated peri-
operatively with 4 doses of alemtuzumab at 0.3 mg/kg/dose. 
All patients also received DSG at a total dose of 36.5 mg/kg. Drug Design, Development and Therapy 2009:3 43
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Despite profound T-cell depletion and therapeutic DSG 
dosing, all patients developed reversible rejection that was 
similar in timing, histology, and transcriptional proﬁ  le to 
that seen in patients treated with alemtuzumab alone. It 
was thus speculated that several chemokines continue to 
be transcribed post-transplantation despite the absence 
of inﬁ  ltrating lymphocytes or monocytes. These chemo-
kines, in turn can serve to gradually accumulate sufﬁ  cient 
residual monocytic antigen presenting cells and allospeciﬁ  c 
lymphocytes to eventually mount an immune response.
Early experiences: summary
Early studies have shown that antibody preconditioning with 
alemtuzumab without maintenance immunosuppression 
failed to achieve tolerance in clinical transplantation whereas 
acceptable short-term patient and graft outcomes could be 
achieved with alemtuzumab induction and minimization 
of immunosuppression (steroid-free CNI-minimization 
protocols).
Alemtuzumab induction and CNI 
avoidance protocols
Sirolimus monotherapy
In a pilot trial conducted by Knechtle and colleagues11 29 
recipients of primary renal allograft transplants were given 
2 doses of alemtuzumab (20 mg/dose) on day 0 and 1 
(ﬁ  rst 24 patients), and on day –1 and 0 (patients 25–29). In 
the ﬁ  rst 24 living donor recipients, sirolimus monotherapy 
was started the day after transplant. Six patients (25%) 
experienced severe acute rejection resulting in one graft 
loss. Most acute rejection episodes occurred within the ﬁ  rst 
3 weeks post-transplant and were predominantly humoral 
(4/6) rather than cellular in nature. Due to the unexpected 
high incidence of early acute humoral rejection (AHR) in the 
ﬁ  rst 24 patients, the subsequent 5 patients were treated with a 
modiﬁ  ed protocol that included alemtuzumab on day –1 and 
0, thymoglobulin on day 1, and steroid tapering over a 14 day 
period. A single dose of thymoglobulin was used to target 
CD52 negative cells which are usually present in 1% to 3% 
of a normal subject’s T cells. In addition, recovery T-cells 
after alemtuzumab induction were found to be largely CD52 
negative. Despite the theoretical advantage of thymoglobulin, 
2 of 5 patients experienced reversible rejection episodes 
within the ﬁ  rst month posttransplant (one with a humoral 
component). Seven of 29 patients with rejection were 
switched to standard triple therapy with tacrolimus, 
mycophenolate mofetil (MMF), and prednisone.
At 3-year follow-up,12 13 patients (46%) had experienced 
acute rejection episodes. Of these, 7 (54%) had a humoral 
component. Graft and patient survival were 96% and 100%, 
respectively. Eighteen patients (67%) were on a steroid-free 
regimen, and 15 of 27 patients with a functioning graft were 
on monotherapy (13 on sirolimus, 1 tacrolimus, and 1 on 
prednisone). No serious infections occurred.
Sirolimus and mycophenolate mofetil 
combination therapy
In view of high acute rejection rates that occurred with 
alemtuzumab induction and sirolimus monotherapy, 
Flechner and colleagues13 performed a pilot study in which 
alemtuzumab induction was followed by sirolimus and 
MMF maintenance therapy in a CNI-free and steroid-free 
immunosuppressive regimen. Twenty two primary renal 
allograft recipients were given alemtuzumab induction 
(30 mg on day 0 and 1), sirolimus and MMF maintenance 
therapy. With a mean follow-up of 15.9 months, patient 
and graft survival were 96% and 87%, respectively. Of 
the 19 surviving grafts, 18 (95%) remained steroid free 
and 15 (79%) were CNI-free. However, acute rejections 
occurred in 8 (36.8%). Of these, 2 were humoral rejections. 
Although the overall infection rates were low, 2 patients 
developed severe acute respiratory distress syndrome at 
month 3 and 7, resulting in mortality in 1 and graft loss in 
the other. No cancer or PTLD was observed. Leukopenia 
was common, requiring MMF dose reduction in 6/22 (27%) 
patients. Although the results of this study suggested that the 
goal of the study was achieved, ie, the majority of patients 
were CNI- and steroid-free at 1 year, there was a concern over 
a higher than expected rate of acute rejection, leukopenia, 
and possible pulmonary toxicity.
Alemtuzumab, MMF, steroids and CNI 
avoidance vs alemtuzumab, CNI, MMF 
and steroids
Retrospective analysis of the OPTN/UNOS database14 
revealed that alemtuzumab induction (n = 690) was associated 
with a lower rate of acute rejection during the ﬁ  rst six months 
post-transplant compared with no induction (n = 4,364), 
ATG (n = 4,930), and Il-2R antibody induction (n = 4,378) 
(2.3% vs 7.6% vs 3.4% vs 4.8%, respectively, p  0.001). 
However, there was an increased incidence of acute rejection 
at 6 months and 1 year with alemtuzumab (14.5% and 19.2%) 
compared to no induction (12.7% and 14.8%, p  0.001), 
ATG (8.2% and 10.2%, p  0.001), and Il-2R antibody Drug Design, Development and Therapy 2009:3 44
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(11.1% and 13.0%, p  0.001) with no difference in adjusted 
relative risk for graft loss. Further analysis demonstrated that 
alemtuzumab recipients receiving FK or CSA, MMF, and 
steroids had increased graft (FK/MMF/steroids, p  0.001), 
CSA/MMF/steroids, p = 0.007) and rejection-free survival 
(FK/MMF/steroids, p = 0.006) over 24 months compared 
with no CNI, MMF, and steroids. It should be noted that 
data on dosing information were not provided, hence it is 
unknown if patients receiving alemtuzumab induction were 
maintained on reduced dose CNI compared to those receiving 
ATG or IL-2R antibody induction.
Low-dose sirolimus vs low-dose CSA 
in combination therapy with low-dose 
MMF
In a prospective, single-center randomized study to determine 
the inﬂ  uence of immunosuppressive agents on regulatory 
T cells (Treg) homeostasis in renal transplant recipients who 
underwent profound T cell depletion with alemtuzumab and 
maintenance therapy with low-dose sirolimus (n = 11) vs 
low-dose CSA (n = 10) in combination therapy with low-
dose MMF, Noris and colleagues15 demonstrated stable graft 
function in both groups at 6, 12, and 24 months. However, 
in sirolimus-treated patients, glomerular filtration rate 
(GFR) was numerically higher than in the CSA group at 
all time points. One patient on sirolimus and two on CSA 
had an episode of steroid responsive acute rejection at 14, 
and 9 and 210 days after transplantation, respectively. The 
investigators further demonstrated that during immune 
reconstitution, CD4+CD25high cells that expressed FOXP3 
underwent homeostatic peripheral expansion that was more 
intense in patients who received sirolimus than in those who 
were given CSA. On the basis of these data, it is hypothesized 
that lymphopenia and calcineurin-dependent signaling could 
be instrumental to achieving pro-tolerogenic Treg expansion 
in the clinical transplant setting.
To test the hypothesis that the expansion of circulating 
CD4+CD15high regulatory T cells might translate into more 
effective protection against chronic allograft injury, the 
same group of investigators16 compared the long-term 
clinical outcomes and biopsy findings of sirolimus- 
(n = 11) vs CSA-treated patients (n = 10). Despite 4-fold 
higher CD4+CD25high Treg counts, sirolimus-treated 
patients – compared to CSA-treated patients, had a 
signiﬁ  cantly higher tubular C4d staining score (sirolimus 
vs CSA: 1.1 ± 0.6 vs 0.2 ± 0.3, p  0.01) with nonsigniﬁ  -
cant trends to higher chronic allograft damage index score, 
faster GFR and RPF decline, and more clinical proteinuria. 
Furthermore, there was no signiﬁ  cant correlation between 
Treg counts and any considered outcome variable in the 
study group as a whole and within each cohort. Hence, 
these data suggest that despite enhanced Treg expression, 
low-dose sirolimus combined to alemtuzumab induction 
and MMF-based-steroid-free maintenance therapy does not 
appreciably protect renal transplant recipients from chronic 
allograft injury and dysfunction.
Alemtuzumab induction and CNI 
avoidance: summary
Alemtuzumab induction and CNI avoidance appear to be 
relatively ineffective in the prevention of acute rejection 
episodes and to lack protection against antibody-mediated 
rejection. Despite the enhanced expression of regulatory 
T cells and its strong antiproliferative effect on alloreactive 
T cells, sirolimus-based immunosuppression in CNI avoidance 
protocols fails to protect renal allograft from chronic injury 
and dysfunction.
Alemtuzumab and minimization 
of immunosuppression (CNI-based 
immunosuppressive protocols 
with or without steroids)
Alemtuzumab induction and reduced 
dose steroids
In a single-center retrospective study, Knechtle and 
colleagues17 reported their experiences with 126 consecutive 
renal allograft recipients who received two doses of 
alemtuzumab on days 0 and 1, in combination therapy with 
very low dose steroids (10 mg methylprednisolone a day), 
MMF, and either tacrolimus or CSA; the outcomes were 
compared with 1115 renal allograft recipients treated at the 
same institution who received either an anti-CD25 antibody 
(n = 799), thymoglobulin (n = 160) or other antibody 
induction therapy (n = 156) in combination with MMF, 
CNI (tacrolimus or CSA), and higher dose steroid (steroid 
taper to 10 mg by 3 months). Follow-up was 12 months for 
the alemtuzumab group and 48 to 72 months for the other 3 
groups. The overall incidence of rejection was lower in the 
alemtuzumab compared to the control groups (p = 0.037). 
At 200 days follow-up, alemtuzumab-treated patients had 
significantly less rejection compared to control groups 
(p = 0.0096). Furthermore, patients with delayed graft 
function had signiﬁ  cantly improved graft survival compared 
to the other cohorts (p = 0.0119). No difference in infections 
or malignancies among the four groups was seen at latest Drug Design, Development and Therapy 2009:3 45
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follow-up. Subsequent analysis at 3-year follow-up revealed 
more viral and fungal infections in the thymoglobulin and 
alemtuzumab group. There was no difference in rejection 
rate. However, graft survival was better in the anti-CD25 
receptor antibody induction group than in the other two 
groups.
Alemtuzumab induction and CNI 
monotherapy (steroid avoidance)
In a prospective randomized three-arm trial in which 
induction therapy with thymoglobulin, alemtuzumab 
(0.3 mg/kg given intravenously on day 0 and day 4), and 
daclizumab were compared, Cianco and colleagues18 have 
shown comparable patient and graft survival, acute rejection 
rates, and renal function among the three treatment groups 
at a median follow-up of 15 months. All patients received 
tacrolimus, MMF, and steroids. However, the alemtuzumab 
group received half the dose of tacrolimus and no steroids 
after the ﬁ  rst week. In addition, 80% of the patients remained 
steroid-free 1 year after transplant.
In a prospective multicenter randomized controlled trial 
comparing alemtuzumab induction (two 20 mg doses given 
intravenously) and low-dose CSA monotherapy (n = 20) 
with conventional triple therapy with CSA, azathioprine, and 
steroids (n = 10), Vathsala and colleagues19 demonstrated 
comparable acute rejection rates, graft and patient survival, 
and renal function between the two treatment groups at 
6 months follow-up. Fifteen of the 20 patients (88%) 
with functioning grafts in the alemtuzumab group were 
steroid free. Thrombocytopenia and the overall incidence 
and spectrum of infections were comparable between the 
two groups.
Alemtuzumab and space-weaning 
tacrolimus monotherapy
Tan and colleagues20 compared the outcomes of 205 living 
donor renal transplant recipients who received alemtuzumab 
induction (30 mg given intravenously on day 0) and spaced-
dose tacrolimus monotherapy with 47 historical controls 
who were transplanted prior to the induction era, and who 
were treated with conventional standard triple therapy with 
tacrolimus, MMF, and prednisone. At a mean follow-up of 
493 days, 7.3% in the alemtuzumab group were on twice 
a day dosing, more than one third (36.6%) were on once 
daily, 22% were on every other day, 17% were on 3 times a 
week, 2% were on twice per week, and 1% were on once per 
week. Approximately 10% were on multiple immunosup-
pressive drugs. Actuarial 1-year patient and graft survival 
were 98.6% and 98.1% in the alemtuzumab group, compared 
to 93.6% and 91.5% in the control group, respectively. The 
incidence of acute cellular rejection (ACR) at 1 year was 
6.8% in the alemtuzumab group and 17.0% in the historic 
control group (p  0.05). There was no cytomegalovirus 
disease or infection. The authors concluded that this study 
conﬁ  rms the short-term safety and efﬁ  cacy of alemtuzumab 
induction and tacrolimus monotherapy in living donor renal 
transplant.
Shapiro and colleagues21 compared thymoglobulin 
(n = 101) or alemtuzumab 30 mg (n = 90) induction and 
minimization of immunosuppression with conventional 
triple immunosuppression with tacrolimus, prednisolone, and 
either MMF or sirolimus (n = 152). In both induction groups 
spaced-weaning tacrolimus monotherapy was attempted 3 to 
4 months posttransplant. There was no signiﬁ  cant difference 
in overall patient and graft survival between both lymphoid 
depleting and historical control groups at 12- to 18-month 
follow-up. However, survival of live donor grafts was better 
in the thymoglobulin and alemtuzumab induction groups 
than in live donor historical controls. There was a signiﬁ  cant 
difference in the incidence and time to acute rejection among 
the three treatment groups. In the thymoglobulin-treated 
patients, the onset of rejection was earlier (p  0.001) and 
the incidence was higher than in either the alemtuzumab or 
historical control patients. Of note, because rejection episodes 
were associated with too rapid weaning in the thymoglobulin 
series, spaced dosing beyond every other day or three times 
a week was not attempted in the alemtuzumab group until 
at least 1 year unless there were speciﬁ  c indications (eg, 
drug nephrotoxicity or neurotoxicity). The incidence of 
rejection during the ﬁ  rst 6 months in alemtuzumab-treated 
patients was 1%. Rejections that occurred after 6 months 
were frequently associated in both the thymoglobulin- and 
alemtuzumab-treated patients with attempts to space wean. 
At 24- to 39-month follow-up, 68% of patients (56/83) 
with functioning grafts in the thymoglobulin-treated group 
were on space doses of maintenance immunosuppression, 
25% were on monotherapy and 7% were on more than one 
immunosuppressant. In the alemtuzumab-treated group, 
74% (62/84) were on space weaning, 14% were on daily 
monotherapy, and 12% received more than a single agent 
at 12-18 month follow-up. The authors concluded that after 
lymphoid depletion, kidney transplantation can be readily 
accomplished under minimal immunosuppression with less 
dependence on late immunosuppression and a better quality 
of life. Alemtuzumab has been suggested to be the more 
effective agent.Drug Design, Development and Therapy 2009:3 46
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Alemtuzumab induction and minimization 
of immunosuppression (CNI-based 
immunosuppressive protocols with 
or without steroids): summary
In low immunological risk renal transplant recipients, excellent 
short- and intermediate-term outcomes can be achieved with 
alemtuzumab induction and CNI minimization with or with-
out steroids. Although alemtuzumab induction may allow 
space-weaning tacrolimus monotherapy, it should be noted 
that the study by Tan and colleagues and that of Shapiro 
and colleagues are limited by their retrospective nature and 
long-term followup is lacking. In addition, in Shapiro’s study, 
acute rejection episodes that occurred after 6 months were 
frequently associated with attempts to space wean.
Alemtuzumab induction in high risk 
renal transplant candidates
High risk renal transplant candidates have variously been 
deﬁ  ned as those with high immunological risk (such as highly 
sensitized or retransplant candidates, African Americans or 
Hispanics), or those at high-risk for delayed graft function 
(such as recipients of organs from expanded criteria donors 
or from donors after cardiac death, prolonged cold ischemia 
time, donor elevated creatinine or donor acute tubular 
necrosis).
The use of alemtuzumab induction in high-risk renal 
transplant candidates has not been consistently shown to 
offer any advantage over traditional induction agents. In the 
following section, selected studies utilizing alemtuzumab 
induction in the so called “high risk” population are 
presented.
African Americans and hispanic ethnicity
In a single-center, prospective, randomized trial consisting 
of predominantly African Americans and Hispanics, 
Cianco and colleagues22 have shown that alemtuzumab 
induction and minimization of immunosuppression were 
less effective than either thymoglobulin or daclizumab and 
higher maintenance immunosuppression. During the study 
period, 90 recipients of deceased donor renal transplants 
were randomized to receive either thymoglobulin during the 
ﬁ  rst week post-transplant (Group A), alemtuzumab on post-
operative day 0 and 4 (Group B), or daclizumab at 1 mg/kg 
on the day of surgery and every 2 weeks × 4 (Group C). 
African Americans and Hispanics comprised more than 50% 
in each group. All patients received tacrolimus, MMF and 
steroid immunosuppression. However, patients in group B 
received half-dose MMF and steroid was withdrawn after 
the ﬁ  rst week post-transplant. At a minimum follow-up of 
27 months, there were no overall group differences in patient 
or graft survival, but a trend towards worse death-censored 
graft survival in group B (p = 0.05). Acute rejection rates 
were not signiﬁ  cantly different among the treatment groups. 
The incidence of chronic allograft nephropathy was higher in 
group B than A and C (p = 0.008). Mean calculated creatinine 
clearances at 24 months were 81.1 ± 5.5, 64.4 ± 4.5, and 
80.7 ± 5.7 mL/min, for groups A, B, and C, respectively 
(p = 0.01 for B vs average A and C).
In a single center retrospective study consisting of the 
ﬁ  rst 75 primary renal transplant patients given alemtuzumab 
induction and minimization of immunosuppression (low-dose 
tacrolimus, reduced dose MMF and steroid withdrawal 
after the ﬁ  rst week posttransplant), Cianco and colleagues23 
demonstrated that while three-year actuarial patient and graft 
survival rates were comparable between African Americans 
(n = 20), Hispanics (n = 32), and non-African Americans 
non-Hispanic (n = 23) (p = NS), higher incidences of biopsy-
proven acute rejection, chronic allograft dysfunction, and 
borderline worse renal function were seen among African 
Americans in comparison with the other patient subgroups.
In a single-center, nonrandomized, retrospective, sequen-
tial study design to evaluate outcomes in kidney transplant 
recipients receiving either a single dose (30 mg) of alem-
tuzumab (n = 123) or basiliximab (n = 155) induction in 
combination therapy with tacrolimus, MMF and steroid 
avoidance, Kaufman and colleagues24 reported a lower rate of 
early rejection (3 months) in the alemtuzumab (4.1%) vs the 
basiliximab (11.6%) group. However, at 1-year follow-up, 
the rejection rates were comparable between the two treat-
ment groups. Further analysis revealed that patient and graft 
survival and rejection rates were nearly identical between 
caucasians (n = 76) and African Americans (n = 28) receiving 
alemtuzumab (96.1% vs 96.4%, respectively). Although 
maintenance immunosuppressive regimens were identical 
in the two induction groups, alemtuzumab-treated patients 
received signiﬁ  cantly less MMF at all time points analyzed 
over a 3-year period, as well as signiﬁ  cantly less tacrolimus 
at all time points analyzed over a 2-year period.
Alemtuzumab induction in kidney 
transplantation from donors after 
cardiac death (DCD)
In a retrospective study comparing the outcomes of induction 
therapy with either alemtuzumab, interleukin-2 receptor 
(IL-2R) antagonists or anti-thymocyte globulin (ATG) in Drug Design, Development and Therapy 2009:3 47
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renal transplantation from donors after cardiac death, Schadde 
and colleagues25 found that induction with alemtuzumab does 
not confer any advantage over traditional induction agents. 
All patients received triple immunosuppression with CNI, 
MMF, and steroids. Patients were stratiﬁ  ed into high-risk and 
low-risk groups. The latter was deﬁ  ned as those with panel 
reactive antibody 20%, retransplants, and African American 
ethnicity. Comparing alemtuzumab to either IL-2R antagonist 
or ATG, the time to acute rejection was not signiﬁ  cantly 
different among the three induction regimen in both high- and 
low-risk groups. While there was no statistically signiﬁ  cant 
difference in graft survival over 3 years, there was a trend 
for worse patient survival in high-risk recipients receiving 
alemtuzumab induction (p = 0.055). It should be noted that 
the high-risk group consisted of a small sample size (Low-
risk group: IL-2R, n = 43; alemtuzumab, n = 61. High-risk 
group: ATG, n = 21; alemtuzumab, n = 20). The antibody 
induction strategies did not lead to signiﬁ  cantly different 
outcomes in patients receiving kidneys from donation after 
cardiac death.
Alemtuzumab induction in high-risk renal 
transplant recipients (The University 
of California at Los Angeles experience)
This is a retrospective review of a single-center prospectively 
maintained database of high-risk renal transplant patients 
who received lymphocyte-depleting antibody induction. 
Patients received thymoglobulin induction (n = 54) in 
2004, and alemtuzumab induction (n = 46) in 2005. “High-
risk” was deﬁ  ned as highly sensitized patients or recipients 
with anticipated delayed graft function such as long cold 
ischemia time (CIT), expanded criteria donor (ECD) 
kidney, donor after cardiac death (DCD), and/or elevated 
donor terminal creatinine). All patients were maintained on 
non-minimization triple therapy consisting of a calcineurin 
inhibitor, MMF, and prednisone. There were no statistical 
differences in the groups with regards to recipient gender, 
ethnicity, living or deceased donor, cold ischemia time, or 
number of HLA matches. One-year patient and graft survival 
rates were comparable between the two treatment groups 
(Thymoglobulin vs alemtuzumab: 96.2% vs 95.1%, and 
90.5% vs 90.7%, respectively). There was no statistically 
significant difference in rejection (alemtuzumab vs 
thymoglobulin: 10.9% vs 16.7%) but humoral rejection was 
more common in the thymoglobulin group. The incidences of 
DGF, viral, and fungal infections were also similar between 
the two treatment groups. Our data support the use of either 
thymoglobulin or alemtuzumab induction in high-risk renal 
transplant recipients. Large randomized, controlled trials 
with long-term follow-up are needed.
Alemtuzumab in high risk renal transplant 
candidates: summary
While alemtuzumab induction and minimization of immuno-
suppression appear to provide effective immunosuppression 
in high-risk renal transplant recipients, an increased rate 
of acute rejection and chronic allograft nephropathy have 
variably been reported. Whether the latter was due to the 
difference in the levels of maintenance immunosuppression 
is speculative. Early studies from our own center suggest 
that alemtuzumab induction and non-minimization of 
immunosuppression is effective in high-risk renal transplant 
recipients. Long-term follow-up is needed.
Discussion
In summary, early experiences have demonstrated that 
alemtuzumab induction alone does not induce tolerance in 
clinical transplantation while alemtuzumab and sirolimus-based 
immunosuppression in CNI-avoidance protocols resulted in 
unacceptable high acute cellular and/or humoral rejection 
rates. In contrast, excellent short- and intermediate- term 
outcomes can be achieved in low-immunological risk renal 
transplant recipients receiving alemtuzumab induction 
in conjunction with reduction in immunosuppression in 
CNI-based steroid avoidance protocols.
Pearl and colleagues26 first studied the phenotype 
and characteristics of post-depletional T cells in renal 
transplant recipients undergoing profound T-cell depletion 
with alemtuzumab or rabbit anti-thymocyte globulin. The 
authors demonstrated that peripheral T cells from transplant 
recipients undergoing aggressive T-cell depletion consist 
almost exclusively of depletion-resistant effector memory 
T cells (CD3+CD4+CD45RA-CD62L-CCR7 phenotype) 
that expand in the ﬁ  rst month and are uniquely prevalent at 
the time of rejection. Furthermore, in vitro studies revealed 
that these cells were resistant to steroids, deoxypergualin 
and sirolimus, but were effectively inhibited by low-dose 
calcineurin inhibitors. Memory cells have been shown to 
be exquisitely sensitive to low concentrations of tacrolimus 
both in terms of proliferation and cytokine production. It is 
conceivable that the selective resistance of effective memory 
T cells to immunosuppressants accounts for the higher 
incidence of acute rejection observed in renal transplant 
recipients receiving alemtuzumab preconditioning and 
sirolimus-based immunosuppression compared to those 
maintained on CNI-based immunosuppression.Drug Design, Development and Therapy 2009:3 48
Pham et al
It has been suggested that the high incidence of humoral 
rejection associated with alemtuzumab induction is due to 
its predominant effect on profound depletion of circulating 
lymphocytes but not circulating monocytes. In a study to 
investigate the role of monocytes in humoral rejection and 
the rates of C4d positivity in unremarkable protocol biopsies 
vs biopsies with acute tubular necrosis (ATN) vs biopsies 
with acute cellular rejection in renal transplant recipients 
receiving alemtuzumab induction Zhang and colleagues27 
demonstrated a low rate of C4d positive staining in both the 
protocol and ATN group. In contrast, a 47% rate of C4d posi-
tivity was noted in the acute cellular rejection (ACR) group. 
Furthermore, in ACR cases, CD68 positive monocytes were 
composed of nearly 60% inﬂ  ammatory cells compared with 
39% CD3 positive lymphocytes. Double staining revealed 
co-localization of positive C4d staining in endothelium and 
marginating CD68 positive monocytes. The high percentage 
of monocytes observed in ACR cases led the authors to 
speculate that monocytes are less sensitive to alemtuzumab 
depletion and are involved in antibody-mediated rejection.
Role of alemtuzumb in renal 
transplantation: the authors’ opinion
The role of alemtuzumab in renal transplantation is currently 
not well deﬁ  ned due to the lack of large, prospective, controlled 
trials and the mixed results obtained from single-center 
experiences. The latter may be due in part to different study 
designs, alemtuzumab dosing regimen, and heterogeneous 
maintenance immunosuppressive therapy. Nonetheless, 
based on currently existing literature, the use of alemtuzumab 
induction and minimization of immunosuppression in a 
regimen consisting of CNI-based immunosuppression with 
or without steroids provides effective immunosuppression in 
low immunological risk renal transplant recipients (eg, living 
or deceased primary transplants, non-sensitized recipients, 
non-African Americans). In high-risk renal transplant 
candidates, antibody preconditioning with alemtuzumab does 
not appear to offer any advantage over traditional induction 
agents. Whether the use of alemtuzumab induction facilitates 
minimization of immunosuppression in high-risk candidates 
needs further studies. Nonetheless, monitoring patients for 
the development of donor speciﬁ  c antibody (DSA) may be 
invaluable in the detection of imminent rejection and the 
information obtained may assist clinicians in redirecting 
therapy. In a retrospective study consisting of a heterogenous 
group of transplant recipients (low- and high-risk recipients) 
receiving alemtuzumab preconditioning with tacrolimus 
monotherapy, Shapiro and colleagues28 have shown that 
intensiﬁ  cation of immunosuppression upon detection of DSA 
in recipients who underwent tacrolimus weaning resulted 
in disappearance of DSA in 40% of patients and excellent 
graft survival at 1- and 2-year follow-up. Whether immune 
monitoring (such as measurement of serum granzyme B and 
perforin) may serve as a useful tool for the early detection of 
rejection and allow safer reduction in immunosuppression 
is a subject of ongoing research. Indeed, the dosing strategy 
for alemtuzumab and the optimal maintenance immunosup-
pressive regimen remain to be deﬁ  ned.
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